Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Rudenko IN, Cookson MR.

Neurotherapeutics. 2014 Oct;11(4):738-50. doi: 10.1007/s13311-014-0284-z. Review.

2.

The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

Rudenko IN, Kaganovich A, Hauser DN, Beylina A, Chia R, Ding J, Maric D, Jaffe H, Cookson MR.

Biochem J. 2012 Aug 15;446(1):99-111. doi: 10.1042/BJ20120637.

3.

LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.

Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR.

Biochem J. 2007 Jul 15;405(2):307-17.

4.

Contribution of GTPase activity to LRRK2-associated Parkinson disease.

Tsika E, Moore DJ.

Small GTPases. 2013 Jul-Sep;4(3):164-70. doi: 10.4161/sgtp.25130. Epub 2013 Jun 10. Review.

6.

GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.

Stafa K, Trancikova A, Webber PJ, Glauser L, West AB, Moore DJ.

PLoS Genet. 2012;8(2):e1002526. doi: 10.1371/journal.pgen.1002526. Epub 2012 Feb 9.

7.

Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.

Lu YW, Tan EK.

J Neurosci Res. 2008 Jul;86(9):1895-901. doi: 10.1002/jnr.21656. Review.

PMID:
18338801
8.

Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.

Gandhi PN, Chen SG, Wilson-Delfosse AL.

J Neurosci Res. 2009 May 1;87(6):1283-95. doi: 10.1002/jnr.21949. Review.

9.

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.

Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ.

Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28.

PMID:
25731749
10.

GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.

Biosa A, Trancikova A, Civiero L, Glauser L, Bubacco L, Greggio E, Moore DJ.

Hum Mol Genet. 2013 Mar 15;22(6):1140-56. doi: 10.1093/hmg/dds522. Epub 2012 Dec 13.

PMID:
23241358
11.

Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations.

Rudi K, Ho FY, Gilsbach BK, Pots H, Wittinghofer A, Kortholt A, Klare JP.

Biosci Rep. 2015 Aug 26;35(5). pii: e00254. doi: 10.1042/BSR20150128.

12.

The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2.

Rudenko IN, Kaganovich A, Langston RG, Beilina A, Ndukwe K, Kumaran R, Dillman AA, Chia R, Cookson MR.

Biochem J. 2017 Apr 24;474(9):1547-1558. doi: 10.1042/BCJ20160909.

PMID:
28320779
13.

Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways.

Sancho RM, Law BM, Harvey K.

Hum Mol Genet. 2009 Oct 15;18(20):3955-68. doi: 10.1093/hmg/ddp337. Epub 2009 Jul 22.

14.

Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.

Li X, Wang QJ, Pan N, Lee S, Zhao Y, Chait BT, Yue Z.

PLoS One. 2011 Mar 1;6(3):e17153. doi: 10.1371/journal.pone.0017153. Erratum in: PLoS One.2011;6(7). doi: 10.1371/annotation/e66e7e90-9503-46b8-91f9-abe4d5056ba1.

15.

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

Rudenko IN, Chia R, Cookson MR.

BMC Med. 2012 Feb 23;10:20. doi: 10.1186/1741-7015-10-20. Review.

16.

A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.

Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva GKh, Markova ED, Limborska SA, Ivanova-Smolenskaya IA.

Eur J Neurol. 2007 Apr;14(4):413-7.

PMID:
17388990
17.

Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.

Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue Z.

J Neurochem. 2007 Oct;103(1):238-47. Epub 2007 Jul 10.

18.

Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.

Huang L, Shimoji M, Wang J, Shah S, Kamila S, Biehl ER, Lim S, Chang A, Maguire-Zeiss KA, Su X, Federoff HJ.

Neurotherapeutics. 2013 Oct;10(4):840-51. doi: 10.1007/s13311-013-0208-3.

19.

Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.

Kramer T, Lo Monte F, Göring S, Okala Amombo GM, Schmidt B.

ACS Chem Neurosci. 2012 Mar 21;3(3):151-60. doi: 10.1021/cn200117j. Epub 2012 Jan 18. Review.

20.

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Greggio E, Cookson MR.

ASN Neuro. 2009 Apr 14;1(1). pii: e00002. doi: 10.1042/AN20090007. Review.

Supplemental Content

Support Center